- Home
- » Tags
- » Turoctocog alfa
Top View
- EHL FVIII Regimens for the Management of Hemophilia A
- WFH Treatment Guidelines 3Ed Chapter 3 Laboratory
- List Item Minutes of the CHMP Meeting 12-15 November 2018
- Specialty Pipeline Monthly Update
- February 13, 2019 Clinical Review
- New Drugs Approved in FY 2019
- International Nonproprietary Names for Pharmaceutical Substances (INN)
- Pre-Authorization (PA) Medication List
- Novel Treatments in Haemophilia and Other Bleeding Disorders: a Periodic EHC Review
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- Issues in Assessing Products for the Treatment of Hemophilia – the Intersection Between Efficacy, Economics, and Ethics
- Current Challenges in the Management of Hemophilia
- Esperoct, INN-Turoctocog Alfa Pegol
- TAG Mail – 25 June 2020
- CHMP September 2017 Minutes for Publication
- Report Template
- Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia a in Italy: Characteristics and Clinical Benefits
- The New Landscape of Therapeutics for the Treatment of Hemophilia
- Stability of Turoctocog Alfa, a Recombinant Factor VIII Product, During Continuous Infusion in Vitro
- June 2018 Monitoring International Trends
- Scientific Programme Sunday, 12. July 2020 Plenary Session State-Of-The-Art on Hemophilia and Rare Bleeding Disorders State-Of-T
- Package Insert
- New Active Substances (Nass) Approved by Six Major Authorities in 2019
- Update to the Red Amber List (March 2021)
- Novoeight, INN-Turoctocog Alfa
- Short-Term Efficacy of Recombinant Porcine Factor VIII in Patients with Acquired Factor VIII Inhibitors
- Managing Patients with Hemophilia: Coordinated Care for Optimal Clinical Outcomes
- Listes De DCI Proposées N'implique Aucune Recommandation En Vue De L'utilisation De La Substance Correspondante En Médecine Ou En Pharmacie
- Evolving Hemophilia Treatment Landscape
- Turoctocog Alfa Pegol Provides Effective Management
- Emerging Insights in the Treatment of Patients with Haemophilia A
- Novel Treatments in Haemophilia and Other Bleeding Disorders: a Periodic EHC Review 2021 Issue One
- (INN) for Biological and Biotechnological Substances
- Scientific Programme Friday, 05. July 2019 Registration
- Setting Pharmacopoeial Standards for Biotherapeutic Products
- Peerview .Com /QUN900 Ensuring the Rapid Recognition and Optimal
- Standouts Melanoma Drug Yervoy, with Seemingly Better Tolerability
- January 2018 a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
- Factor Products
- Scientific Programme Sunday, 12. July 2020 PL 01, Plenary Session Test
- April 2018 a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
- 11Beffbcaff5d6995a07dec57393
- PRAC Draft Agenda of Meeting 13-16 January 2020
- Medicines Not Reimbursed Through National Prices and Directly Commissioned by Nhs England V14 Changes to Version 13
- A View Into Upcoming Specialty and Traditional Drugs JANUARY 2019
- Novel Treatments in Haemophilia and Other Bleeding Disorders: a Periodic EHC Review Issue One
- Monitoring International Trends
- Tenofovir Alafenamide
- Novel Treatments in Haemophilia and Other Bleeding Disorders: a Periodic EHC Review 2020 Issue Two
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances